Öz
Amaç
Alkole bağlı olmayan yağlı karaciğer hastalığı (NAFLD), küresel yaygınlığı giderek artan yaygın bir kronik karaciğer hastalığıdır. Magnezyum ve D vitamini birçok fizyolojik işlev için gereklidir. Ancak bu elementlerin NAFLD ve karaciğer fibrozisi ile olası ilişkileri hala net değildir. Bu çalışmanın amacı, serum magnezyum ve D vitamini düzeyleri ile aspartat aminotransferaz/trombosit oranı (APRI) ve fibrosis-4 (FIB-4) indeksi gibi karaciğer fibrozis göstergeleri arasındaki ilişkiyi değerlendirmektir.
Yöntem
Bu retrospektif çalışmada, hepatik steatoz değerlendirmesi için karın ultrasonu yapılan 414 hastanın verileri incelendi. Demografik veriler, laboratuvar bulguları ve görüntüleme sonuçları kaydedildi. Hastalar, karaciğerde yağlanma varlığı ve şiddetine göre sınıflandırıldı. Biyokimyasal fibrozis skorları ile NAFLD arasındaki ilişkiler değerlendirildi.
Bulgular
Serum magnezyum düzeyleri, FIB-4 indeksi ile ters yönde ilişkiliydi (r=-0,101, p=0,045) ve düşük risk grubunda (FIB-4 <1,45) daha yüksekti (p=0,006). D vitamini, hepatik steatoz şiddetiyle (r=-0,107, p=0,031) ve diyabetik olmayan/hiperlipidemik olmayan hastalarda APRI skorlarıyla ters ilişki gösterdi (r=-0,383, p=0,044). Prediyabetik hastalarda düşük magnezyum düzeyleri, artmış karaciğer yağlanmasıyla ilişkiliydi (p=0,013). Non-yüksek yoğunluklu lipoprotein kolesterol, steatoz şiddetiyle pozitif korelasyon gösterdi (p<0,001).
Sonuç
Magnezyum ve D vitamini, karaciğer yağlanması ve fibrozisine karşı koruyucu etkilere sahip olabilir. Fibrozis indeksleriyle olan ters ilişkileri, potansiyel anti-fibrotik etkilerini düşündürmektedir. Özellikle prediyabetik hastalarda magnezyum, NAFLD patogenezinde rol oynayabilir. Bu bulgular, magnezyum ve D vitamininin fibrozis değerlendirmesi ve NAFLD yönetimindeki potansiyel rollerinin daha fazla araştırılmasını desteklemektedir.
Anahtar Kelimeler: Alkole bağlı olmayan yağlı karaciğer hastalığı, magnezyum, D vitamini, HOMA-IR indeksi, fibrozis-4 indeksi
Kaynakça
Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274-85.
Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313:2263-73.
Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28:27-38.
Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis. 2008;28:370-9.
Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed). 1986;292:13-5.
Kruger FC, Daniels CR, Kidd M, et al. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. S Afr Med J. 2011;101:477-80.
Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cárdenas E, Sánchez-Avila F, Vargas-Vorácková F. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol. 2008;7:350-7.
Maselli DB, Bazerbachi F, Matar R, et al. Sa1563 Fib-4 index correlates with measures of nash activity in subjects with nash and low burden of fibrosis. Gastroenterology. 2020;158:S-351.
Sahin T, Arikan BT, Serin A, et al. The utility of noninvasive scoring systems for prediction of hepatic steatosis in liver transplantation donor candidates. Transplant Proc. 2019;51:2383-6.
Lu L, Hao K, Hong Y, et al. Magnesium isoglycyrrhizinate reduces hepatic lipotoxicity through regulating metabolic abnormalities. Int J Mol Sci. 2021;22:5884.
Fengler VH, Macheiner T, Goessler W, Ratzer M, Haybaeck J, Sargsyan K. Hepatic response of magnesium-restricted wild type mice. Metabolites. 2021;11:762.
Benetti E, Mastrocola R, Chiazza F, et al. Effects of vitamin D on insulin resistance and myosteatosis in diet-induced obese mice. PLoS One. 2018;13:0189707.
Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. J Clin Endocrinol Metab. 2004;89:447-52.
Dawson-Hughes B, Staten MA, Knowler WC, et al. Intratrial exposure to vitamin D and new-onset diabetes among adults with prediabetes: a secondary analysis from the vitamin D and type 2 diabetes (D2d) Study. Diabetes Care. 2020;43:2916-22.
Barchetta I, De Bernardinis M, Capoccia D, et al. Hypovitaminosis D is independently associated with metabolic syndrome in obese patients. PLoS One. 2013;8:68689.
Sonsuz A, Baysal B. Karaciğer yağlanması ve non alkolik steatohepatit. Güncel Gastroenteroloji. 2011;15:98-106.
Liu M, Yang H, Mao Y. Magnesium and liver disease. Ann Transl Med. 2019;7:578.
Rayssiguier Y, Chevalier F, Bonnet M, Kopp J, Durlach J. Influence of magnesium deficiency on liver collagen after carbon tetrachloride or ethanol administration to rats. J Nutr. 1985;115:1656-62.
Romani AM. Magnesium homeostasis and alcohol consumption. Magnes Res. 2008;21:197-204.
Lu L, Chen C, Li Y, et al. Magnesium intake is inversely associated with risk of non-alcoholic fatty liver disease among American adults. Eur J Nutr. 2022;61:1245-54.
Li W, Zhu X, Song Y, et al. Intakes of magnesium, calcium and risk of fatty liver disease and prediabetes. Public Health Nutr. 2018;21:2088-95.
Lima Mde L, Cruz T, Rodrigues LE, et al. Serum and intracellular magnesium deficiency in patients with metabolic syndrome--evidences for its relation to insulin resistance. Diabetes Res Clin Pract. 2009;83:257-62.
Rodríguez-Hernández H, Gonzalez JL, Rodríguez-Morán M, Guerrero-Romero F. Hypomagnesemia, insulin resistance, and non-alcoholic steatohepatitis in obese subjects. Arch Med Res. 2005;36:362-6.
Song Y, He K, Levitan EB, Manson JE, Liu S. Effects of oral magnesium supplementation on glycaemic control in type 2 diabetes: a meta-analysis of randomized double-blind controlled trials. Diabet Med. 2006;23:1050-6.
Rahim MA, Mitra P. Serum magnesium level of newly detected patients with glucose intolerance and its comparison with serum magnesium level of age and sex matched healthy volunteers. J Med (Bangladesh). 2018;19:95-9.
Black LJ, Jacoby P, She Ping-Delfos WC, et al. Low serum 25-hydroxyvitamin D concentrations associate with non-alcoholic fatty liver disease in adolescents independent of adiposity. J Gastroenterol Hepatol. 2014;29:1215-22.
Chung GE, Kim D, Kwak MS, et al. The serum vitamin D level is inversely correlated with nonalcoholic fatty liver disease. Clin Mol Hepatol. 2016;22:146-51.
Liu T, Xu L, Chen FH, Zhou YB. Association of serum vitamin D level and nonalcoholic fatty liver disease: a meta-analysis. Eur J Gastroenterol Hepatol. 2020;32:140-7.
Kim HS, Rotundo L, Kothari N, Kim SH, Pyrsopoulos N. Vitamin D is associated with severity and mortality of non-alcoholic fatty liver disease: a US population-based study. J Clin Transl Hepatol. 2017;5:185-92.
Luger M, Kruschitz R, Kienbacher C, et al. Prevalence of liver fibrosis and its association with non-invasive fibrosis and metabolic markers in morbidly obese patients with vitamin D deficiency. Obes Surg. 2016;26:2425-32.
Patel YA, Henao R, Moylan CA, et al. Vitamin D is not associated with severity in NAFLD: results of a paired clinical and gene expression profile analysis. Am J Gastroenterol. 2016;111:1591-8.
Bertol FS, Araujo B, Jorge BB, Rinaldi N, De Carli LA, Tovo CV. Role of micronutrients in staging of nonalcoholic fatty liver disease: a retrospective cross-sectional study. World J Gastrointest Surg. 2020;12:269-76.
Corbin KD, Pittas AG, Desouza C, et al. Indices of hepatic steatosis and fibrosis in prediabetes and association with diabetes development in the vitamin D and type 2 diabetes study. J Diabetes Complications. 2023;37:108475.
de Almeida JP, Liberatti LS, Barros FE, et al. Profile of oxidative stress markers is dependent on vitamin D levels in patients with chronic hepatitis C. Nutrition. 2016;32:362-7.
Wang Z, Peng C, Wang P, et al. Serum vitamin D level is related to disease progression in primary biliary cholangitis. Scand J Gastroenterol. 2020;55:1333-40.
Zelber-Sagi S, Salomone F, Yeshua H, et al. Non-high-density lipoprotein cholesterol independently predicts new onset of non-alcoholic fatty liver disease. Liver Int. 2014;34:128-35.
Wang K, Shan S, Zheng H, Zhao X, Chen C, Liu C. Non-HDL-cholesterol to HDL-cholesterol ratio is a better predictor of new-onset non-alcoholic fatty liver disease than non-HDL-cholesterol: a cohort study. Lipids Health Dis. 2018;17:196.
Tutunchi H, Naeini F, Ebrahimi-Mameghani M, Mobasseri M, Naghshi S, Ostadrahimi A. The association of the steatosis severity, NAFLD fibrosis score and FIB-4 index with atherogenic dyslipidaemia in adult patients with NAFLD: a cross-sectional study. Int J Clin Pract. 2021;75:14131.
